NCT02581189View on ClinicalTrials.gov

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

CompletedOBSERVATIONAL

Enrollment

565

Participants

Timeline

Start Date

October 13, 2015

Primary Completion Date

December 20, 2017

Study Completion Date

December 20, 2017

Conditions

Chronic Hepatitis C

Interventions

DRUG

Ombitasvir/paritaprevir/ritonavir

Co-formulated tablet

DRUG

Dasabuvir

Tablet

DRUG

Ribavirin

Tablet

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

IST GmbH, Germany

INDUSTRY

collaborator

Cato Research

INDUSTRY

lead

AbbVie

INDUSTRY